AVRO

AVROBIO, Inc. [AVRO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AVRO Stock Summary

Top 10 Correlated ETFs

AVRO


Top 10 Correlated Stocks

AVRO


In the News

04:03 29 Sep 2023 AVRO

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives

After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates.

08:51 29 Sep 2023 AVRO

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

06:00 29 Sep 2023 AVRO

How to Handle Penny Stocks Volatility in 2023

Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.

11:43 29 Sep 2023 AVRO

Why Is AVROBIO (AVRO) Stock Up 83% Today?

AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an investigational hematopoietic stem cell ( HSC ) gene therapy program.

04:33 29 Sep 2023 AVRO

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

12:21 29 Sep 2023 AVRO

AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.

12:55 29 Sep 2023 AVRO

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

09:12 29 Sep 2023 AVRO

Trading Penny Stocks? Top Stock Market News for February 9th, 2022

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:30 29 Sep 2023 AVRO

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks

The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

07:00 29 Sep 2023 AVRO

AVROBIO to Present at Cowen's 2nd Annual Genetic Medicines Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen's 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throu

AVRO Financial details

Company Rating
Neutral
Market Cap
67.69M
Income
53.09M
Revenue
0
Book val./share
2.77
Cash/share
2.83
Dividend
-
Dividend %
-
Employees
78
Optionable
No
Shortable
Yes
Earnings
06 Nov 2023
P/E
1.28
Forward P/E
-
PEG
-0.09
P/S
-
P/B
0.56
P/C
0.54
P/FCF
-0.91
Quick Ratio
10.71
Current Ratio
11.05
Debt / Equity
0.02
LT Debt / Equity
0
-
-
EPS (TTM)
1.2
EPS next Y
-
EPS next Q
-
EPS this Y
-12%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-378.18%
-
-
-
-
SMA20
1.99%
SMA50
14.07%
SMA100
97.44%
Inst Own
45.46%
Inst Trans
0.88%
ROA
40%
ROE
61%
ROC
-0.04%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
44.53M
Shs Float
29.54M
-
-
-
-
Target Price
-
52W Range
0.56-1.93
52W High
-
52W Low
-
RSI
50.5
Rel Volume
0.12
Avg Volume
1.09M
Volume
125.15K
Perf Week
-1.91%
Perf Month
0.65%
Perf Quarter
58.76%
Perf Half Y
46.67%
-
-
-
-
Beta
1.56155
-
-
Volatility
0.01%, 0.04%
Prev Close
0%
Price
1.54
Change
-0.65%

AVRO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-3.45-2.63-3.27-2.75-2.42
Operating cash flow per share
-2.8-2.47-2.73-2.29-2.22
Free cash flow per share
-2.94-2.52-2.76-2.34-2.23
Cash per share
9.46.827.174.422.12
Book value per share
9.096.787.023.951.72
Tangible book value per share
9.096.787.023.951.72
Share holders equity per share
9.096.787.023.951.72
Interest debt per share
0000.340.41
Market cap
223.7M552.21M504.71M164.99M31.05M
Enterprise value
97.4M365.16M245.03M-9.63M-44.05M
P/E ratio
-4.83-7.66-4.26-1.4-0.29
Price to sales ratio
00000
POCF ratio
-5.94-8.16-5.11-1.68-0.32
PFCF ratio
-5.67-7.97-5.05-1.64-0.32
P/B Ratio
1.832.971.980.970.41
PTB ratio
1.832.971.980.970.41
EV to sales
00000
Enterprise value over EBITDA
-2.11-4.82-2.040.080.42
EV to operating cash flow
-2.59-5.4-2.480.10.45
EV to free cash flow
-2.47-5.27-2.450.10.45
Earnings yield
-0.21-0.13-0.23-0.71-3.41
Free cash flow yield
-0.18-0.13-0.2-0.61-3.14
Debt to equity
0000.090.23
Debt to assets
0000.070.17
Net debt to EBITDA
2.732.472.161.470.71
Current ratio
12.2613.9616.0910.278.23
Interest coverage
000530.54-352.62
Income quality
0.810.930.830.820.92
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.050.020.010.030
Capex to revenue
00000
Capex to depreciation
-4.82-1.86-0.98-1.76-0.19
Stock based compensation to revenue
00000
Graham number
26.5720.0322.7515.639.7
ROIC
-0.38-0.4-0.47-0.64-1.12
Return on tangible assets
-0.35-0.36-0.44-0.58-1.02
Graham Net
8.596.316.723.641.46
Working capital
119.41M181.68M250.63M179.76M87.56M
Tangible asset value
122.18M186.01M254.34M169.48M75.37M
Net current asset value
118.73M181.2M250.35M164.78M71.1M
Invested capital
0000.090.23
Average receivables
772.5K1.84M2.35M2.63M1.48M
Average payables
1.66M3.37M3.32M3.08M1.94M
Average inventory
-772.5K-1.84M-2.35M-2.63M-1.48M
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.38-0.39-0.47-0.69-1.41
Capex per share
-0.14-0.06-0.03-0.06-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.65-0.520.74-0.551.53
Operating cash flow per share
-0.67-0.38-0.54-0.46-0.33
Free cash flow per share
-0.67-0.38-0.54-0.46-0.33
Cash per share
3.032.652.111.642.83
Book value per share
2.712.241.721.22.77
Tangible book value per share
2.712.241.721.22.77
Share holders equity per share
2.712.241.721.22.77
Interest debt per share
0.350.350.40.480.07
Market cap
40.2M28.01M31.09M44.04M41.93M
Enterprise value
-77.1M-72.75M-44.01M-9.95M-80.38M
P/E ratio
-0.35-0.310.24-0.460.16
Price to sales ratio
00000
POCF ratio
-1.38-1.71-1.31-2.17-2.86
PFCF ratio
-1.37-1.7-1.31-2.17-2.86
P/B Ratio
0.340.290.410.830.34
PTB ratio
0.340.290.410.830.34
EV to sales
00000
Enterprise value over EBITDA
2.813.211.740.395.19
EV to operating cash flow
2.654.431.860.495.49
EV to free cash flow
2.644.411.850.495.49
Earnings yield
-0.7-0.821.05-0.551.61
Free cash flow yield
-0.73-0.59-0.77-0.46-0.35
Debt to equity
0.130.160.230.40.02
Debt to assets
0.10.120.170.250.02
Net debt to EBITDA
4.284.452.972.147.9
Current ratio
11.117.88.236.211.05
Interest coverage
-97.45-207.07-134.35-101.69137.39
Income quality
1.040.710.950.81-0.22
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.010.0100
Capex to revenue
00000
Capex to depreciation
-0.42-0.24-0.44-0.020
Stock based compensation to revenue
00000
Graham number
6.295.135.373.859.75
ROIC
-0.21-0.20.35-0.320.53
Return on tangible assets
-0.19-0.180.31-0.290.5
Graham Net
2.512.061.460.952.6
Working capital
129.3M110.04M87.56M60.65M117.18M
Tangible asset value
118.34M98.09M75.37M53M122.04M
Net current asset value
114.18M94.83M71.1M42.32M117.05M
Invested capital
0.130.160.230.40.02
Average receivables
2.9M2.97M1.63M269.5K270K
Average payables
2.03M921K1.1M487.5K831K
Average inventory
5.88M6.34M3.12M-692K988.5K
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.24-0.230.43-0.460.55
Capex per share
00000

AVRO Frequently Asked Questions

What is AVROBIO, Inc. stock symbol ?

AVROBIO, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol AVRO

What is AVROBIO, Inc. stock quote today ?

AVROBIO, Inc. stock price is $1.54 today.

Is AVROBIO, Inc. stock public?

Yes, AVROBIO, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap